Absci Corporation announced a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation?? platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.

Absci will contribute its pioneering generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding and milestone payments, in addition to royalties on product sales. Absci's Integrated Drug Creation platform harnesses generative AI and a suite of scalable wet-lab technologies.

It aims to enhance the likelihood of successful development outcomes for biologic drug candidates by optimizing multiple drug attributes concurrently and expanding the universe of drug targets to include those previously deemed "undruggable" such as GPCRs and ion channels. Today's agreement comes on the heels of Absci's publication on the design and validation of de novo antibodies using Absci's 'zero-shot' generative AI model and follows additional collaborations with leading biopharmaceutical, healthcare and technology organizations.